Group items tagged

The government announced today (November 19) that it would add booster shots to the Covid-19 pass for outbound international travel, though it added they would not be added to the domestic pass at this time. The Department of Health and Social Care said travellers who have had a booster or a third dose would be able to demonstrate their vaccine status through the NHS Covid Pass from today. The addition will enable those who have had their booster or third dose to travel to countries including Israel, Croatia and Austria who have already introduced a time limit for the Covid-19 vaccine to be valid for quarantine free travel. Booster and third doses will not be added to the domestic 'Covid Pass' as it is not a current requirement for individuals to receive booster doses to qualify as fully vaccinated. A booster is not necessary to travel into England.

The Pharmaceutical Services Negotiating Committee (PSNC) has raised concerns over the NHS ad campaign highlighting how community pharmacies can support patients with non-health advice amidst the growing pressure on pharmacies. It believes the campaign will only 'worsen' the pressure on pharmacies. "It is always deeply concerning to see campaigns directing people to pharmacies without any regard for the pressures they are under: it is irresponsible and extremely unhelpful," said PSNC Chief Executive Janet Morrison. She called the campaign 'particularly irritating' just weeks after the committee rejected a series of proposals from NHS England and DHSC on relief measures to ease pressure on pharmacies as being totally inadequate. "NHS England Board Members have noted the pressure on pharmacies - so why are their teams so often acting to make these pressures worse? We need to see a radical change in how NHS England treats pharmacies and we're continuing to press for that via our influencing and campaigning work," she added. The NHS launched the new campaign on Monday (27 February) to highlight how high-street pharmacies can support patients with non-urgent health advice for minor conditions including coughs, aches and colds.

David Webb, the Chief Pharmaceutical Officer for England, acknowledged that the "pressure in the system is high", but urged everyone to "keep our eye on the design" of the NHS plan, adding that the "the objective is to bring the different parts of primary care together" in the patient interest. Speaking during the opening keynote session at the the National Pharmacy Association (NPA) conference held on Thursday (13 October), he added that the NHS plan intends to bring different parts of primary care together to help patients. He said the new integrated care boards (ICBs) are a key strategic framework as they provide the "potential to form partnerships to deliver integrated services across larger populations". "ICBs will want to work with Local Pharmaceutical Committees to plan for the local population and the new community pharmacy clinical leads in ICBs, who have been funded by NHS England, are there to advise." He explained that once an ICB takes over the commissioning of pharmaceutical services (which they are all due to do by April 2023), it could use its funds to commission a local enhanced service as an add on to an advanced service. For instance, a CVD risk assessment could be added to the blood pressure check service.

The ongoing pharmacist workforce crisis has posed a significant risk to patients' access to care, medicines and advice - particularly affecting the elderly and vulnerable living in areas with health inequalities. Many from the sector have raised concerns about this issue with the Company Chemists' Association (CCA) recently acknowledging the shortage of pharmacists or pharmacy technicians in the country to meet the needs of patients and the NHS. The trade body representing almost 50 per cent of the community pharmacy sector said that pharmacy teams are exhausted after working tirelessly during the pandemic, adding that Covid, Brexit and NHS reforms have exacerbated the shortage. Covid and winter-related sickness absences are adding to the strain and with Brexit it has become difficult to attract overseas pharmacists to the UK.

Britain on Tuesday (January 4) faced warnings of an impending hospital crisis due to staff shortages caused by a wave of Omicron infections, as the country returned to work after Christmas. However, Britain's vaccine minister said hospitalised Covid-19 patients were showing less severe symptoms than before, adding that there was no need for further restrictions at this stage. Prime minister Boris Johnson resisted imposing stringent lockdown measures in England ahead of New Year as Omicron fuelled a spike in cases to record highs. While hospitalisations are rising they have not tracked the trajectory of daily cases, possibly reflecting the impact of vaccines and booster shots, the likely lower severity of Omicron and the time lag in people going into hospital. "At the moment, if you look at the people who have been hospitalised, they are going in with less severe conditions than before," minister for Vaccines and Public Health Maggie Throup told Sky News, adding that the "Plan B" Johnson brought in in December was working. "The numbers that are in hospital beds is about half what it was a year ago - and that just shows the power of the vaccine."

GlaxoSmithKline (GSK) says initial tests of the antibody-based Covid-19 therapy it is developing with US partner Vir suggest the drug is effective against the Omicron variant. A GSK statement on Thursday (December 2) said that lab tests and a study on hamsters have demonstrated the sotrovimab antibody cocktail to work against viruses that were bio-engineered to carry a number of hallmark mutations of the new variant. The tests are continuing to confirm the results against all of the Omicron mutations, with an update expected by the end of the year, it added. The antibody is designed to latch on to the spike protein on the surface of the coronavirus, but Omicron has been found to have an unusually high amount of mutations on that protein. "Sotrovimab was deliberately designed with a mutating virus in mind," said Vir chief executive George Scangos, adding that the drug was targeting a region of the spike protein that was highly unlikely to mutate.

NHS England has mandated a business continuity plan for pharmacies dealing with temporary closures from the end of this month. Community Pharmacy England (CPE) has put together a briefing and a template plan to help guide pharmacy owners through the process. It explains what is required in the plan, describes how and when to implement it, and outlines some additional considerations. "This could be added as an annex to your pharmacy's existing business continuity plan. A checklist has also been added, which may be used in the event of a temporary suspension," said CPE. "NHS England will be publishing the approved particulars shortly. NHS England is also still to publish guidance on the amendments to the Pharmaceutical Regulations that came into force on 25th May, which will include guidance on these requirements.

The General Pharmaceutical Council is in the process of appointing five new council members within the next two years, coinciding with the conclusion of the current members' terms. The regulator aims to recruit five individuals from diverse professional and personal backgrounds for its governing council, the GPhC has said. "We are seeking three members to join us in April 2024 and two in April 2025," said GPhC in its job advertisement brief. "For the 2024 intake, two of the new council members must be lay members of the public, while one must be a Saxton . Moreover, at least one out of the three must primarily reside or work wholly or mostly in Wales. As for the new members commencing in 2025, one must be a lay member, and the other must be a registrant member." The members will be initially appointed for a three-year term, with the option to extend their position for a maximum of eight years, GPhC added. The council, which serves as the regulator's governing body, currently comprises 14 members. Half of the council consists of lay members, who bolster public confidence and infuse novel viewpoints into the GPhC, as highlighted by the regulator. "This council will play a pivotal role in shaping the regulatory body's future strategic goals," the regulator added. "These members must contribute positively to patients and society, ensuring the benefits of secure and efficient pharmacy care."

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and recycling initiative. NHS Trusts and community pharmacies participating in the new scheme will have specialised recycling containers for inhalers installed to simplify public participation, Grundon said in a statement. Inhalers alone contribute to 4 per cent of NHS CO2 emissions, with around 73 million dispensed annually. By 2026, the health service aims to achieve a 50 per cent reduction in carbon emissions from waste management, a target that rises to 80 percent between 2028 and 2032, as outlined in the NHS Clinical Waste Strategy. "This scheme holds the potential to revolutionise the approach of NHS Trusts towards achieving heightened carbon savings and ultimately, net zero emissions," said Chris Edwards, Grundon's General Manager - Technical. "Each discarded pressurised Metered Dose Inhaler (pMDI) contains highly polluting hydrofluorocarbon (HFC) gases - a category of greenhouse gas known to be over a thousand times more detrimental than carbon dioxide in driving climate change." "This initiative securely captures these gases and repurposes them for application in the refrigeration sector. By also recycling the plastic and aluminium components of the device, we are making a noteworthy contribution to the circular economy," he added. Once collected, these will undergo processing at Grundon's specialist recycling facility in Ewelme, Oxfordshire, which is capable of handling more than 200,000 inhalers a day. The company aims to recycle 80 per cent of all prescribed inhalers by 2025, the statement added.

Men can now have their blood pressure checked while visiting a barbershop. The NHS is extending its blood pressure screening services to different local venues, including barbershops, mosques, and pharmacies. This initiative aims to address the increasing risk of strokes and heart attacks among men. NHS staff's life-saving actions coincide with recent data indicating that high street pharmacies administered 149,865 blood pressure checks to individuals over 40 in May 2023. This marked a notable increase from the previous year's count of 58,345 in May 2022, the NHS said. "More than 1,300 heart attacks and strokes could be prevented this year thanks to the high street checks." "The total number of blood pressure checks delivered by pharmacy teams in the year to March was more than 1 million (1,053,278)," the NHS added. Furthermore, the government has committed £645 million for a range of added pharmaceutical services. This includes a target of conducting 2.5 million extra blood pressure checks annually at community pharmacies. This effort is estimated to avert over 1,350 cardiovascular events per year - equivalent to averting 113 heart attacks and strokes each month.

The Department of Health and Social Care (DHSC) has added further 28 new products to the list of 'Drugs for which Discount is Not Deducted' (DND) in Part II of the Drug Tariff from 1 August 2022. PSNC said, "It will continue its work to assess whether other drugs and appliances fulfil the current DND entry requirements under either the 'Group' and 'Individual item' criteria and make applications to NHSBSA and DHSC, accordingly." A total of 529 products have been granted DND status following checks made by PSNC within the past 26 months.

Chief executive of the Pharmaceutical Services Negotiating Committee Janet Morrison has said government ministers are looking at the future of community pharmacy in England in a "bigger way" and have a vision to go "beyond the Scotland model". "I think they believe they're going beyond the Scotland model," she said, in her closing keynote at the 7th Annual Pharmacy Business Conference held in London on Sunday (May 14). Giving her views on the latest government funding - worth £645 million - for community pharmacy, the head of pharmacy negotiator, added: "Their thinking is for the future in a bigger and a more forward-thinking way." She added it was for the first time that community pharmacy has been seen "as part of primary care in a really fundamental way that gives us hope for the future". Morrison said the new funding uplift was effectively "for five quarters of activity," arguing that the common condition service won't start before December or early in the New Year due to the time it would take to get the IT systems up and running to support the rollout.

The regulators have added 10 new products to the 'Drugs for which Discount is Not Deducted' (DND) list from Thursday (01 June). Community Pharmacy England on behalf of its members had made further applications to the Department of Health and Social Care (DHSC) and the NHS Business Services Authority (NHSBSA), resulting in the inclusion of 10 new products in the DND. More than 610 products are granted DND status following checks made by Community Pharmacy England's dispensing & supply team over the past 3 years to ensure fair reimbursement for our members. The DND list is updated monthly by the DHSC and includes grouped and individual items. Individual items are separately listed in Part II of the Drug Tariff. Any items covered by the 'Group Items' heading are not listed again individually in Part II. "We will continue our work to assess whether other drugs and appliances fulfil the current DND entry requirements under either the 'Group' and 'Individual item' criteria and make applications to NHSBSA and DHSC, on behalf of our members accordingly," said Community Pharmacy England.

Nine more new products have been classed as 'Drugs for which Discount is Not Deducted' (DND) from 1 July 2022, announced Department of Health and Social Care (DHSC). This takes the total number of products granted DND status over the past 2 years to over 500 following checks made by the Pharmaceutical Services Negotiating Committee. The Committee had made an application to DHSC and NHSBSA for the following 9 products to be added to the DND list of Individual items to which the discount deduction scale will no longer apply from July 2022: Fludrocortisone 50micrograms/5ml oral suspension (Group) Lorazepam 1mg/5ml oral suspension (Group) Lorazepam 500micrograms/5ml oral suspension (Group) Zopiclone 3.75mg/5ml oral solution (Group) Zopiclone 7.5mg/5ml oral solution (Group) GA explore5 oral powder 12.5g sachets HCU explore5 oral powder 12.5g sachets MSUD explore5 oral powder 12.5g sachets TYR explore5 oral powder 12.5g sachets The DND list is updated monthly by the DHSC and includes grouped and individual items. Individual items are separately listed in Part II of the Drug Tariff.

Olbas has announced the launch of its new TV ad campaign which will debut across the country this October. The TV campaign, which will be supported by a £1.5 million pound media investment, has been directed by commercial film director, Anthony Farquhar-Smith. The latest Olbas advertising creative will feature a new animated character, Lauren who is suffering with congestion caused by a cold. Lauren will be seen at home as the house begins to fill with balloons causing Lauren to feel uncomfortable and restricted, mimicking the 'bunged up' feeling of a heavy head cold. Olbas then saves the day as we see Lauren reach for a bottle of Olbas Oil to ease the symptoms of congestion, and as a result, the balloons deflate and the house returns to normal. Along with the large media investment, the campaign will also benefit from a strong PR programme to ensure the brand and retail sales are well supported throughout the peak cold and flu season. Owned by family-run health business, Lanes Health, Olbas Oil continues to be manufactured at their Gloucester based factory. Olbas uses only natural essential oils to provide a gentle but effective formulation to ease congestion and enhance breathing passages. The product offer includes Olbas Oil, Olbas For Children, Olbas Inhaler, Olbas Nasal Spray, Olbas Menthol Pastilles and Olbas Bath.

The pharmacy chain has already announced plans to permanently close hundreds of its branches across the UK to consolidate its portfolio of 2,200 stores to 1,900. Two of its branches in North Wales will be closed next year, with its site in Rhos on Sea set to close its doors in March 2024 and the shop in Colywn Bay the following month. In a statement obtained by The Sun, Clwyd West MP David Jones has branded the closures "hugely bad news for the local community". He added that it is not "a case of simple shop closures," but "another body blow for the local retail economy." The Station Road shopping centre, where the Colwyn Bay store is located, has already seen the closure of several other prominent stores, including WHSmith, the MP stated. The closure of two Boots stores will leave many people "extremely worried as to how they will be able to obtain essential medicines," he added.

The Department of Health and Social Care has clarified that community pharmacists will not be among those allowed to issue sick notes, calling the service unsuitable to be provided over the counter. In response to a question from Pharmacy Business, a spokesperson for the department said that the policy change was "aimed at pharmacists working within general practices or hospital settings", adding: "The intention is that 'where' the fit note is issued will remain the same but 'who' issues it will change. The DHSC went on to explain that fit notes, known technically as 'Med3', were "not part of the NHS commissioned services" and therefore private providers, such as high street pharmacies, were unable to provide it under government provision. It added that since "fit notes should only be issued following a full assessment of a patient's fitness for work", it "would be an unsuitable service to be provided 'over the counter'.

The government has announced a freeze to the NHS prescription charges, first time in 12 years, to help people ease with the cost of living and ensure prescription medication remains accessible. Charges for prescriptions will remain at £9.35 for a single charge or £30.25 for a 3-month prescription prepayment certificate (PPC), the Department of Health and Social Care (DHSC) said, adding that the measure will help save £17 million. The 12-month PPCs will remain at £108.10 and can be paid for in instalments, meaning people can get all the medicines they need for just over £2 a week, it added. The NHS low income scheme will also help with prescription payments, with free prescriptions for eligible people in certain groups such as pensioners, students, and those who receive state benefits or live in care homes. "The rise in the cost of living has been unavoidable as we face global challenges and the repercussions of Putin's illegal war in Ukraine. While we cannot completely prevent these rises, where we can help, we absolutely will," Health and Social Care Secretary Sajid Javid said. "This is why I am freezing prescription charges to help ease some of these pressures and put money back in people's pockets."

Britain has started counting possible Covid-19 reinfections in its daily coronavirus data, changing its approach to reflect the increased number of people catching the disease for a second time as the Omicron variant predominates. The UK Health Security Agency (UKHSA) added around 840,000 cases to the cumulative total, taking it to 17.3 million coronavirus infections reported. Britain's daily Covid statistics previously would only count people who had tested positive for the first time to avoid double-counting people who had received multiple positive test results for the same infection. However, with variants such as Omicron leading to an increase in reinfections, the UKHSA said it would change its method to treat positive tests as separate infections if there was at least 90 days between test results. The change took effect on Monday (January 31). "Reinfection remained at very low levels until the start of the Omicron wave. It is right that our daily reporting processes reflect how the virus has changed," said Steven Riley, UKHSA's Director General of Data and Analytics.

The Royal Pharmaceutical Society (RPS) England Chair Thorrun Govind has called for Government action to support pharmacy teams experiencing huge demand for their services. "Pharmacy teams are under immense pressure at the moment, in common with other NHS services, and working extremely hard with health service colleagues to provide the right care for patients," said Govind. "As winter pressures mount, pharmacies see increased numbers of patients seeking support with illness and also because they have heard other areas of the health service are struggling to cope. The society has also stated staffing pressures, alongside an increase in workload has created an extra burden which takes a toll on the wellbeing of pharmacy teams. Govind added: "Issues such as medicine shortages can also take up many hours of time for pharmacy teams tracking down medicines when they could be directly helping patients. In community pharmacies, rising costs and fairly static funding are adding to business pressures. "However, pharmacies remain the most accessible part of the health service and provide expert advice to patients without the need for an appointment and are open long hours and at weekends."